South Korea's Pharmaceutical Imports Reach Record High
Recent data shows that in 2024, South Korea's total pharmaceutical imports from the United States surpassed $1 billion, marking a new high in recent years. Anti-cancer drugs, rare disease treatments, and vaccines constituted more than half of this total. Industry insiders indicate this trend reflects South Korea's increasing reliance on U.S. supply for advanced medical products, highlighting significant gaps in the local pharmaceutical industry in some key areas.
Share of High-End Pharmaceuticals Continues to Expand
Within the import composition, the proportions of anti-cancer and rare disease treatment drugs are consistently rising, indicating an increased demand for cutting-edge medicines in South Korea's healthcare system. Notably, some drugs have virtually no substitutes on the global market, placing South Korea in a passive position in price negotiations and supply assurance. For instance, Pfizer's cancer injectables and Novartis's Zolgensma are unique American products; any supply disruption would directly impact patient treatment.
Experts Warn of Dependency Risks
Experts generally believe that excessive reliance on pharmaceutical imports from a single country could not only lead to price volatility but also jeopardize the stability of supply chains amid tariff negotiations or geopolitical tensions. Particularly under the Trump administration's continuously adjusting trade policies, pharmaceutical tariffs might become a potential negotiation tool. Experts emphasize that South Korea should learn from the global supply chain crisis during the pandemic and accelerate the establishment of an emergency drug reserve mechanism.
Government Calls for Diversified Import Channels
South Korean lawmaker Kim Mi-ae explicitly stated in her report that the government should formulate a comprehensive plan, including diversifying import sources, establishing a strategic reserve system, and supporting domestic research and production. She pointed out that without action, the uncertainty of South Korea in the global pharmaceutical market will only intensify in the future, posing challenges to public health and potentially increasing long-term healthcare costs.
Pressure on Domestic Industry
Industry insiders note that South Korean pharmaceutical companies have a competitive edge in the production of generic and some conventional drugs, but they are still catching up in the field of high-end biopharmaceuticals and rare disease medications. This leads to a higher dependency on U.S. imports for domestic patients. Some scholars suggest that the government should guide policies and invest funds to encourage local companies to accelerate research in gene therapy, biopharmaceuticals, and other areas to gradually narrow the gap.
Outlook and Measures
In the long run, the security of the pharmaceutical supply chain has become a national strategic issue. South Korea needs to ensure the stability of existing supplies while actively seeking cooperation with Europe, Japan, and emerging markets to spread risks. At the same time, establishing a national reserve of essential life-saving drugs will provide a buffer against potential future emergencies. Experts believe that if a balance between diversification and localization can be achieved, South Korea could enhance industrial autonomy while ensuring public health.
